昆藥集團(600422.SH)子公司擬收購貝克浙江30%股權
格隆匯8月14日丨昆藥集團(600422.SH)公佈,公司的子公司昆明貝克諾頓製藥有限公司(“貝克諾頓”)擬出資人民幣約1213.48萬元向自然人王友昆購買其所持有的貝克諾頓(浙江)製藥有限公司(“貝克浙江”)15%股權;貝克諾頓擬出資人民幣約1213.48萬元向自然人鍾曉明購買其所持有的貝克浙江15%股權。此次交易完成後,貝克諾頓將持有貝克浙江100%股權。
公告顯示,貝克諾頓製藥公司現有頭孢和青黴素類抗生素、消化系統用藥、青蒿素系列抗瘧藥等30多個產品,包括膠囊、片劑、口服混懸劑、口服溶液劑等劑型,主要產品有頭孢克洛分散片、頭孢克肟膠囊、阿莫西林膠囊、阿莫西林克拉維酸鉀幹混懸劑、奧美拉唑腸溶片、呱西替柳幹混懸劑等。現有四個口服制劑(頭孢類、青黴素類、普通類固體制劑和液體制劑)生產車間及10餘條現代化生產線,均已通過國家2010版GMP認證,其中生產抗瘧藥的普通製劑車間於2006年和2012年兩次通過世界衞生組織(WHO)GMP認證。
2016年度實現主營業務收入5915萬元、2017年度實現主營業務收入7016萬元、2018年實現主營業務收入7767萬元。
此次交易目的是加快完成集團構建完整產業,促進集團生產銷售業務整合,降低生產運營成本,保持產品在市場中的競爭能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.